A Phase 1/2/3 Study of TSHA-102 Gene Therapy in Females With Rett Syndrome (REVEAL Pivotal Study)
← catalyst calendarNCT05606614 · readout ≤ 1,776 d
Sponsored by Taysha Gene Therapies, Inc. (industry) · TSHA — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · Single · Treatment
Enrollment
17actual
Sites
9
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-06 | actual | When the study began enrolling |
| Primary completion | Jun 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Rett Syndrome
Intervention
- Genetic: TSHA-102
Primary outcomes
what the primary-completion date above is the date OFPart A: Safety and Tolerability of TSHA-102
measured Baseline through Week 52
Part B: Efficacy of TSHA-102
measured Baseline through Week 52
Publications
- PMID 38723617 — linked by the registry
- PMID 38254921 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · TSHA's whole pipeline · Catalyst calendar · Every registered study · What changed